



HHS Public Access

Author manuscript

Chemistry. 2018 January 26; 24(6): 1259–1263. doi:10.1002/chem.201705772.

Published in final edited form as:

Chemistry. 2018 January 26; 24(6): 1259–1263. doi:10.1002/chem.201705772.

Phenols as Diamagnetic T_2 -Exchange Magnetic Resonance Imaging Contrast Agents**

Jia Zhang,

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Yuguo Li,

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Stephanie Slania,

Department of Biomedical Engineering, The Johns Hopkins University, Baltimore, Maryland, United States

Nirbhay N. Yadav,

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, United States

Jing Liu,

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. Graduate College, Southern Medical University, Guangzhou, Guangdong, China

Rongfu Wang,

Department of Nuclear Medicine, Peking University First Hospital Beijing, China

Jianhua Zhang,

Department of Nuclear Medicine, Peking University First Hospital Beijing, China

Prof. Martin G. Pomper,

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

Prof. Peter C. van Zijl,

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, United States

Prof. Xing Yang, and

**Financial support from the NIH grants R03CA197470, R03EB021573, R01CA211087, R21CA215860, R01EB019934, and R01EB015032, and the Chinese National Thousand Young Talents Program is acknowledged.

Correspondence to: Xing Yang; Guanshu Liu.

Supporting information for this article is given via a link at the end of the document.

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. Department of Nuclear Medicine, Peking University First Hospital Beijing, China

Prof. Guanshu Liu

The Russell H. Morgan Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States. F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, United States

Abstract

While T_2 -exchange ($T_{2\text{ex}}$) NMR phenomena have been known for decades, only recently there has been a resurgence of interest to develop $T_{2\text{ex}}$ MRI contrast agents. One indispensable advantage of $T_{2\text{ex}}$ MR agents is the possibility of using non-toxic and/or bio-important diamagnetic compounds with intermediate exchangeable protons. In this study, we screened a library of phenol-based compounds and determined their $T_{2\text{ex}}$ contrast (exchange relaxivity, $r_{2\text{ex}}$) at 9.4 T. Our results showed that the $T_{2\text{ex}}$ contrast of phenol protons allows them to be detected directly by MRI at a mM concentration level. We also studied the effect of chemical modification of the phenol on the $T_{2\text{ex}}$ MRI contrast through modulation of exchange rate and chemical shift. This study provides a guideline for using endogenous and exogenous phenols for $T_{2\text{ex}}$ MRI contrast. As a proof-of-principle application, we demonstrated phenol $T_{2\text{ex}}$ contrast can be used to detect enzyme activity in a tyrosinase-catalyzed catechol oxidation reaction.

Graphical Abstract

Phenol-based T_2 -exchange magnetic resonance imaging contrast agents are screened. With the inherent T_2 -exchange effect, catechol is utilized as the substrate for the detection of tyrosinase activity in a label-free manner.



Keywords

Contrast agents; MRI; phenols; T_2 -exchange; tyrosinase

The utility of magnetic resonance imaging (MRI) contrast agents is indispensable for both clinical diagnoses and research. Among the current available agents that have been developed in the last four decades, relaxivity agents, i.e., T_1 and T_2/T_2^* MRI contrast agents, are the two most widely used types. Most of these agents are metal-based, either lanthanide or transition metal, which raises more concerns recently on their potential toxicity or disturbance of these metal ions and imposes the extra difficulty for the clinical translation

of new agents. Recently, a renewed interest has been drawn to a category of compounds that possess labile protons that can efficiently exchange with surrounding water molecules and result in an observable change in water T_2 relaxation time.^[1] This type of MRI contrast agents, namely T_2 -exchange (T_{2ex}) agents, includes both lanthanide-based agents^[2] and non-metallic diamagnetic compounds such as iopamidol^[3], glycogen^[4], and glucose^[5] to generate MRI contrast, which paves a new avenue for directly using readily translatable diamagnetic agents for biomedical imaging. This can be considered as a natural extension of diamagnetic chemical exchange saturation transfer (CEST) contrast.^[6] The relationship between chemical properties (chemical shift difference from water ω and proton exchange rate k_{ex}) and T_{2ex} contrast has been described using the Swift-Connick equation (Supporting information, Eq. S4–S5).^[7] We simulated the equation in Figures 1A and S1, which describes the dependence of the relaxivity r_{2ex} of an agent on its offset frequency from the exchanging partner (water protons here) ω and the exchange rate k_{ex} . As shown, at a given field strength, both ω and k_{ex} can strongly affect relaxivity and thus the T_{2ex} based contrast. A high ω is always favorable for generating strong T_{2ex} contrast, while there is an optimal k_{ex} at each ω (Figure 1B). According to Figure 1C, for ω values ranging from 1 ppm to 12 ppm, the optimal k_{ex} ranges from 2.5 kHz (for 1 ppm) to 30.2 kHz (for 12 ppm) at 9.4 T, which is faster than the favorable exchange rate to generate CEST contrast. Compared with the much larger shifts in paramagnetic shift agents,^[2c] the limited ω creates a sensitivity barrier for most diamagnetic agents (mostly <6 ppm). For example, as shown in Figure 1B, the theoretical maximum r_{2ex} values at 1.5, 4.6, 9.3 and 12 ppm are $0.017 \text{ s}^{-1} \text{ mM}^{-1}$ ($k_{ex} = 3.8 \text{ kHz}$), $0.053 \text{ s}^{-1} \text{ mM}^{-1}$ ($k_{ex} = 11.6 \text{ kHz}$), $0.106 \text{ s}^{-1} \text{ mM}^{-1}$ ($k_{ex} = 23.4 \text{ kHz}$), and $0.137 \text{ s}^{-1} \text{ mM}^{-1}$ ($k_{ex} = 30.2 \text{ kHz}$), respectively.

Phenols represent a class of diamagnetic agents potentially well suited for T_{2ex} contrast. The aromatic ring and lower pK_a for the phenolic proton, compared with alcohols, enable a higher ω and k_{ex} .^[8] With judicious modification of chemical structures, ω values of up to 12 ppm have been achieved.^[9] In addition, phenol protons are present in a variety of biologically important compounds, such as amino acids, neurotransmitters (e.g. dopamine and serotonin), and commonly used drugs (e.g. acetaminophen). The establishment of controllable exchange for the optimal T_{2ex} effect could potentially help to balance the sensitivity and specificity, promoting the development of clinically useful diamagnetic phenols as T_{2ex} contrast agents.

With phenol (**1**) as the model compound, we first characterized its T_{2ex} contrast ability at 9.4 T, a field strength commonly used for pre-clinical studies. Phenol has an exchangeable hydroxyl proton 4.6 ppm shifted from water (or 9.3 ppm in the NMR spectrum versus TMS, Figure S2), with a pK_a of 10. As shown in Figures 2A–2B, phenol clearly exhibits concentration-dependent and pH-dependent T_{2ex} effects, with an observed transverse exchange relativity (r_{2ex}) of, for example, $0.023 \text{ s}^{-1} \text{ mM}^{-1}$ at pH 7.4 and 37 °C. It should be noted that phosphate can catalyze proton exchanges,^[10] which is negligible when exchange is fast (i.e., pH > 7.0) but become significant at lower pHs where exchange is slow (Figure S3). Therefore, we performed the pH study using water but not PBS solutions. Figure 2C shows that the maximum contrast was obtained at pH 6.5. The k_{ex} values of phenol were then estimated by fitting the measured r_{2ex} values at three temperatures (20, 30, and 37 °C)

to the Swift-Connick equation (Figure S4, Eqs. S4&S5), under the assumption that k_{ex} increases at higher temperature.^[7] As shown in Figure 2D, the k_{ex} of phenol was estimated to be 23.4 and 44.7 kHz for pH 7.0 and pH 7.4 respectively, which falls in the fast regime of $r_{2\text{ex}}-k_{\text{ex}}$ curve, and 1.6 and 8.0 kHz for pH 6.0 and pH 6.5 respectively, which falls in the slow regime of $r_{2\text{ex}}-k_{\text{ex}}$ plot. This phenomenon can be explained by base-catalyzed proton exchange characteristic of exchangeable protons.^[10] At pH 6.5, the k_{ex} is most close to the ω difference (i.e., $2\pi \times 4.6 \text{ (ppm)} \times 400 \text{ (Hz/ppm)} = 11.6 \times 10^3 \text{ rad s}^{-1}$) to generate the maximal $T_{2\text{ex}}$ effect. Both fast and slow rates of exchange will reduce the magnitude of $T_{2\text{ex}}$ effect. Interestingly, when k_{ex} decreased with dropping pH, CEST signals from the phenolic proton appeared (Figure 2E). This process is in line with the condition of $k_{\text{ex}} \ll \omega$, which is a prerequisite for observing CEST effect. At pH 6.0, there was a strong CEST signal at 4.6 ppm (Figure 2E), consistent with the chemical shift value (i.e., 9.3 ppm, Supporting information S2) measured using NMR spectroscopy (compared to the water signal at 4.7 ppm).

The relaxivity results of studying a series of phenol analogues in PBS at pH 7.4 and 37 °C are listed in Scheme 1. Electron donating substitution (NH_2 , OMe, Me) *para*- to the phenol OH (**2–4**) slightly reduced ω and more significantly reduced the k_{ex} towards the optimum, resulting in an overall increase of $r_{2\text{ex}}$. In sharp contrast, electron withdrawing substitution (Cl, COOH) *para*- to the phenol OH (**6** and **7**) dramatically increased the k_{ex} against the optimum value and making these agents unsuitable for generating $T_{2\text{ex}}$ contrast. Both electron donating and withdrawing modification (OH and COOH) at meta-position were tolerated with only slightly changes in overall $r_{2\text{ex}}$ (**9** and **10**).

Intramolecular hydrogen bonded phenols have been reported to achieve higher ω (8.6–12.0 ppm) and applied for CEST MR imaging.^[11] For example, salicylic acid (**11**) can achieve a ω of 9.3 ppm. However, its exchange rate is too slow ($k_{\text{ex}} \sim 0.4 \text{ kHz}^{[11]}$) to generate $T_{2\text{ex}}$ contrast ($r_{2\text{ex}} = 0.003 \text{ s}^{-1} \text{ mM}^{-1}$), despite its favorable chemical shift. Attempts to increase the k_{ex} by the introduction of *ortho*-/*para*- electron withdrawn groups proved to be successful in **12–15**. Higher $T_{2\text{ex}}$ contrast was found for these, for example a $r_{2\text{ex}}$ of $0.059 \text{ s}^{-1} \text{ mM}^{-1}$ and k_{ex} of 7.1 kHz for **12** at ω of 9.0 ppm, and a $r_{2\text{ex}}$ of $0.046 \text{ s}^{-1} \text{ mM}^{-1}$ and k_{ex} of 5.2 kHz for **15** at ω of 12.0 ppm. In 10 mM PBS at pH 4.5, the $r_{2\text{ex}}$ for **15** was $0.11 \text{ s}^{-1} \text{ mM}^{-1}$, close to its theoretical maximum ($0.137 \text{ s}^{-1} \text{ mM}^{-1}$). This experimental largest $r_{2\text{ex}}$ is comparable in magnitude to that of glucose at 9.4 T,^[5] suggesting the potential opportunity to be used for relevant biomedical studies.

To further demonstrate potential applications, we applied $T_{2\text{ex}}$ MRI to monitor the bioactivity of tyrosinase (TYR) in a label-free manner. Tyrosinase is an enzyme catalyzing the hydroxylation of phenolic substrates to catechol derivatives, further oxidized to ortho-quinone products (Figure 3A).^[12] These reactions have been recognized as key processes in the biosynthetic pathway of some natural pigments, making TYR the targeting enzyme for treating hypopigmentation-related problems.^[13] Recent studies also showed that the accumulated TYR can be considered as an important biomarker of melanoma cancer,^[14] and TYR imbalance is related to Parkinson's disease due to its effect on dopamine neurotoxicity.^[15] Therefore, the non-invasive detection of TYR activity is pivotal for diagnosis and treatment monitoring. Our results show that the natural substrate, catechol, has a $r_{2\text{ex}}$ of

0.077 s⁻¹ mM⁻¹ at pH 6.5 and 25 °C (Figure S8A), while the product, ortho-quinone, has no T_{2ex} contrast-enhancing ability due to the lack of exchangeable hydroxyl protons, which allows the direct detection of TYR activity by observing the changes in the T_2 relaxation time of the system. To demonstrate that, we incubated 10 mM catechol (pH 6.5, 25 °C) with TYR at different concentrations (U, units/mL). As shown in Figure 3B, the presence of TYR significantly decreased the R_2 rates of the samples. Because TYR itself did not produce noticeable T_{2ex} effects (Figure S8B), the differences in T_{2ex} between the samples incubated with different concentrations of TYR were attributed to the conversion of catechol to ortho-quinone. The change in T_{2ex} thus allows the quantitative detection of enzyme activity without the need for additional agents. For example, as shown in Figure 3C, we calculated the conversion ratio based on the T_{2ex} of the samples. This is just a first example of using the T_{2ex} contrast not only to detect the presence of phenol derivatives but also to monitor their changes and reactions.

While the T_2 contrast-enhancement ability of diamagnetic agents is weaker than those of paramagnetic metallic agents, this new approach has several important advantages for *in vivo* applications. Firstly, similar to CEST MRI, T_{2ex} contrast can be used to detect enzyme activity^[16] in a label-free way. Evidenced by the TYR study, the changes in many physiologically or pathologically important molecules (in response to treatments) can be observed directly without disturbing the system. Indeed, we showed that two naturally abundant compounds (tyrosine **16**, $r_{2ex} = 0.10$ s⁻¹ mM⁻¹ and serotonin **18**, $r_{2ex} = 0.08$ s⁻¹ mM⁻¹) can be used as T_{2ex} agents. The concentrations generating 1% MRI contrast, which is on the same order of magnitude as functional MRI signal changes, are 2 and 2.4 mM, respectively, in short T_2 tissues (e.g. muscle, $T_2 \sim 50$ ms^[17]), or 1 and 1.2 mM respectively, in long T_2 tissues (e.g. grey matter, $T_2 \sim 100$ ms^[17]), implying the potential for *in vivo* applications. It should be noted that the detection limit in a MRI study is defined by the contrast-to-noise ratio (CNR) and a threshold of CNR of 2 is typically used to achieve a 95% probability that the contrast before and after the injection of an agent is different^[18]. As CNR is defined by $\Delta S / S$ times signal-to-noise ratio (SNR), the minimally required SNR for reliably detecting 1% signal change is 282, suggesting a high SNR (i.e., ~ 300) should be used to reliably detect a 1% signal change. On the other hand, previous studies showed that the local concentration of exogenously injected agents can reach >4 mM in the tumor^[19] and >5 mM in the blood^[20] in animal studies, and >69 mM in the kidney in human studies^[21], indicative of the possibility of achieving sufficient local concentrations for generating T_{2ex} contrast. Finally, while pH may be a confounding factor for quantifying the concentration in the targeted tissue, its effect on quantification can be minimized by using the dynamic contrast enhanced imaging scheme, an approach widely used in CEST MRI studies for quantitatively measuring tissue uptake of pH sensitive CEST agents.^[22] Nevertheless, this approach is particularly useful for monitoring the *ex vivo* drugs or agents, for example, in tumors (typically have longer T_2 values), without any additional imaging labeling, in a theranostic manner.^[22a, 23]

In summary, we screened a library of phenol-based compounds and determined their T_{2ex} effects. The T_{2ex} contrast was delicately modulated by means of chemical modification, which affected exchange rate and chemical shift. Current results show that the T_{2ex} effect of

phenols can be optimized for MR imaging directly at a mM concentration level. Understanding the T_{2ex} mechanism of phenolic protons shall contribute to the interpretation of endogenous T_2 signals and the development of new exogenous T_{2ex} agents. As the first proof-of-concept, we applied this contrast mechanism to the detection of enzymatic activity of tyrosinase by directly utilizing the changes in T_{2ex} relaxation times when the natural substrate is converted to the product. These phenols are also expected to affect the parameter $T_{1\rho}$, the longitudinal relaxation time in the rotating frame, which is also exchange dependent.^[24]

Experimental Section

Aqueous solutions of each chemical were freshly prepared prior to each MRI measurements either in water or phosphate buffered saline (PBS). When not otherwise noted, the sample phantoms were warmed to 37 °C. All MRI measurements were performed using a Bruker 9.4 T vertical MR scanner with a 20-mm birdcage transmit/receive coil. T_2 relaxation times were acquired using a Carr-Purcell-Meiboom-Gill (CPMG) method as previously described^[5]. Briefly, a T_2 preparation module, with 16 echo times ranging from 20 ms to 10.24 sec, was added in the front of a Rapid Acquisition with Relaxation Enhancement (RARE) pulse sequence. The imaging parameters were: TR/TE = 25000/4.3 ms, RARE factor = 16, a 64x64 acquisition matrix with a spatial resolution of *c.a.* 250x250 μm^2 , and slice thickness of 1 mm. The acquisition time for each T_2 -weighted image was 1 min 40 s.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

1. Leigh JS. *J Mag Reson* (1969). 1971; 4:308–311.
2. a) Soesbe TC, Merritt ME, Green KN, Rojas-Quijano FA, Sherry AD. *Magn Reson Med*. 2011; 66:1697–1703. [PubMed: 21608031] b) Soesbe TC, Togao O, Takahashi M, Sherry AD. *Magn Reson Med*. 2012; 68:816–821. [PubMed: 22213371] c) Daryaei I, Pagel MD. *Res Rep Nucl Med*. 2015; 5:19–32. [PubMed: 27747191]
3. Aime S, Nano R, Grandi M. *Invest Radiol*. 1988; 23(Suppl 1):S267–270. [PubMed: 3198360]
4. Gore JC, Brown MS, Mizumoto CT, Armitage IM. *Magn Reson Med*. 1986; 3:463–466. [PubMed: 3724426]
5. Yadav NN, Xu J, Bar-Shir A, Qin Q, Chan KW, Grgac K, Li W, McMahan MT, van Zijl PC. *Magn Reson Med*. 2014; 72:823–828. [PubMed: 24975029]
6. a) van Zijl PCM, Lam WW, Xu J, Knutsson L, Stanisz GJ. *Neuroimage*. 2017b) Jones KM, Pollard AC, Pagel MD. *J Magn Reson Imaging*. 2017c) Liu G, Song X, Chan KW, McMahan MT. *NMR Biomed*. 2013; 26:810–828. [PubMed: 23303716] d) van Zijl P, Yadav NN. *Mag Reson Med*. 2011; 65:927–948.
7. Swift TJ, Connick RE. *J Chem Phys*. 1962; 37:307–320.
8. Puar M, Grunwald E. *Tetrahedron*. 1968; 24:2603–2610.
9. Yang X, Yadav NN, Song X, Ray Banerjee S, Edelman H, Minn I, van Zijl PC, Pomper MG, McMahan MT. *Chem Eur J*. 2014; 20:15824–15832. [PubMed: 25302635]
10. Liepinsh E, Otting G. *Magn Reson Med*. 1996; 35:30–42. [PubMed: 8771020]
11. Yang X, Song X, Li Y, Liu G, Banerjee SR, Pomper MG, McMahan MT. *Angew Chem Int Ed*. 2013; 52:8116–8119.

12. a) Korner A, Pawelek J. *Science*. 1982; 217:1163–1165. [PubMed: 6810464] b) Sanchez-Ferrer A, Rodriguez-Lopez JN, Garcia-Canovas F, Garcia-Carmona F. *Biochim Biophys Acta*. 1995; 1247:1–11. [PubMed: 7873577]
13. Briganti S, Camera E, Picardo M. *Pigment Cell Res*. 2003; 16:101–110. [PubMed: 12622786]
14. Angeletti C, Khomitch V, Halaban R, Rimm DL. *Diagn Cytopathol*. 2004; 31:33–37. [PubMed: 15236262]
15. Asanuma M, Miyazaki I, Ogawa N. *Neurotox Res*. 2003; 5:165–176. [PubMed: 12835121]
16. a) Bar-Shir A, Liu G, Liang Y, Yadav NN, McMahon MT, Walczak P, Nimmagadda S, Pomper MG, Tallman KA, Greenberg MM, van Zijl PC, Bulte JW, Gilad AA. *J Am Chem Soc*. 2013; 135:1617–1624. [PubMed: 23289583] b) Liu G, Liang Y, Bar-Shir A, Chan KW, Galpoththawela CS, Bernard SM, Tse T, Yadav NN, Walczak P, McMahon MT, Bulte JW, van Zijl PC, Gilad AA. *J Am Chem Soc*. 2011; 133:16326–16329. [PubMed: 21919523] c) Haris M, Singh A, Mohammed I, Ittyerah R, Nath K, Nanga RP, Debrosse C, Kogan F, Cai K, Poptani H, Reddy D, Hariharan H, Reddy R. *Sci Rep*. 2014; 4:6081. [PubMed: 25124082]
17. Stanisz GJ, Odrobina EE, Pun J, Escaravage M, Graham SJ, Bronskill MJ, Henkelman RM. *Magn Reson Med*. 2005; 54:507–512. [PubMed: 16086319]
18. Haacke, EM. *Magnetic Resonance Imaging: Physical Principles and Sequence Design*. Wiley-Liss; 1999. p. 349
19. Chen LQ, Howison CM, Jeffery JJ, Robey IF, Kuo PH, Pagel MD. *Magn Reson Med*. 2014; 72:1408–1417. [PubMed: 24281951]
20. a) Schuenke P, Koehler C, Korzowski A, Windschuh J, Bachert P, Ladd ME, Mundiyanapurath S, Paech D, Bickelhaupt S, Bonekamp D, Schlemmer HP, Radbruch A, Zaiss M. *Magn Reson Med*. 2017; 78:215–225. [PubMed: 27521026] b) Deuel RK, Yue GM, Sherman WR, Schickner DJ, Ackerman JH. *Science*. 1985; 228:1329–1332. [PubMed: 4001946]
21. Jones KM, Randtke EA, Yoshimaru ES, Howison CM, Chalasani P, Klein RR, Chambers SK, Kuo PH, Pagel MD. *Mol Imaging Biol*. 2017; 19:617–625. [PubMed: 27896628]
22. a) Li Y, Chen H, Xu J, Yadav NN, Chan KW, Luo L, McMahon MT, Vogelstein B, van Zijl PC, Zhou S, Liu G. *Oncotarget*. 2016; 7:6369–6378. [PubMed: 26837220] b) Chan KW, McMahon MT, Kato Y, Liu G, Bulte JW, Bhujwala ZM, Artemov D, van Zijl PC. *Magn Reson Med*. 2012; 68:1764–1773. [PubMed: 23074027]
23. a) Lock LL, Li Y, Mao X, Chen H, Staedtke V, Bai R, Ma W, Lin R, Li Y, Liu G, Cui H. *ACS Nano*. 2017; 11:797–805. [PubMed: 28075559] b) Liu H, Jablonska A, Li Y, Cao S, Liu D, Chen H, Van Zijl PC, Bulte JW, Janowski M, Walczak P, Liu G. *Theranostics*. 2016; 6:1588–1600. [PubMed: 27446492] c) Ngen EJ, Bar-Shir A, Jablonska A, Liu G, Song X, Ansari R, Bulte JW, Janowski M, Pearl M, Walczak P, Gilad AA. *Mol Pharm*. 2016; 13:3043–3053. [PubMed: 27398883]
24. a) Jin T, Autio J, Obata T, Kim SG. *Magn Reson Med*. 2011; 65:1448–1460. [PubMed: 21500270] b) Cobb JG, Li K, Xie J, Gochberg DF, Gore JC. *Magn Reson Imaging*. 2014; 32:28–40. [PubMed: 24239335]




Figure 1. Simulations with the Swift-Connick equation showing the dependence of T_{2ex} contrast on exchange rates and chemical shifts. A) Simulated r_{2ex} as a function of labile proton ω and k_{ex} at $B_0 = 9.4 \text{ T}$; B) Simulated r_{2ex} dependence on k_{ex} for ω values of 1.5, 4.6, 9.3 and 12 ppm respectively; C) Optimal k_{ex} for the ω range from 1 ppm to 12 ppm.






Figure 2.

T_{2ex} contrast of phenol (1). A) T_2 -weighted MR images at echo times (TE) of 20 and 2560 ms as well as the corresponding T_2 maps as a function of concentration; B) The concentration dependence of transverse relaxation rates (R_2) of phenol in water at the concentration ranging from 2 to 20 mM at 37 °C at four different pHs; C) The measured r_{2ex} of phenol at different pHs; D) The estimated k_{ex} of phenols at different pHs and their positions on the r_{2ex} - k_{ex} theoretical curve obtained by using the Swift-Connick equation. All data points are shown as the average of three samples (see Supporting Information for experimental details); E) CEST MRI signals of phenol at different pHs as quantified by MTR_{asym} plots from 0 to 6 ppm.

**Figure 3.**

The Detection of tyrosinase enzyme activity using T_{2ex} MRI. A) Schematic illustration of the conversion of catechol (high T_{2ex} contrast or hypointense MRI signal on the T2w image shown below) to benzoquinone (no T_{2ex} contrast or hyperintense MRI signal on the T2w image shown below) by the catalysis of tyrosinase. B) Pseudo-colored R_2 maps of 10 mM catechol solutions (in PBS, 10 mM, pH 6.5), containing different concentration of tyrosinase after reaction for 1.5 h at 25 °C. C) Correlation of transverse relaxation rate and conversion ratio with concentration of tyrosinase. Note: U is the unit of tyrosinase concentration and stands for unit/mL.

**Scheme 1.**

r_{2ex} of phenols tested. Experimental conditions: pH = 7.4, 37 °C and $B_0 = 9.4$ T. r_{2ex} value were derived from the concentration-dependent R_2 fitting line, and ω was obtained from either NMR spectra or CEST spectra. See Figure S5–S7 (Supporting Information) for details. ^a) r_{2ex} data for compounds with multiple OHs were normalized for the contribution of single OH. ^b) Due to interaction between the two *ortho*-OHs, k_{ex} calculated *via* treating them independently may have significant error. ^c) k_{ex} were not estimated due to the potential minor contribution from other exchangeable protons.